Spark Therapeutics (ONCE), focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases.
ONCE’s products include voretigene neparvovec, which is in Phase III clinical trial for the treatment of genetic blinding conditions called inherited retinal diseases caused by non-sex-linked, autosomal recessive, or biallelic mutations in the RPE65 gene; and SPK-CHM that is in Phase I/II clinical trial for the treatment of choroideremia.
ONCE's products also comprise SPK-7001 that is in Phase 1/2 trial for choroideremia; SPK-9001, which is in Phase 1/2 trial for hemophilia B; and SPK-8011 that is in Phase 1/2 trial hemophilia A. In addition, its product candidates and development programs include SPK-FVIII program to treat hemophilia A; SPK-TPP1 program for the treatment of a form of Batten disease and Huntington's disease; RhoNova for the treatment of rhodopsin-linked autosomal dominant retinitis pigmentosa; and SPK-LHON for treating Leber hereditary optic neuropathy, as well as preclinical programs in development for the treatment of rare genetic blinding conditions, hematologic disorders, and other neurodegenerative diseases.
ONCE has collaboration agreement with Pfizer, Inc. for the development and commercialization of SPK-FIX product candidates in its gene therapy program for the treatment of hemophilia B.
Spark Therapeutics, Inc. was founded in 2013 and is headquartered in Philadelphia, Pennsylvania.
- December 10, 2015 - 10:12am | Research Notes
- December 8, 2015 - 7:42am | Henry'omics
- November 27, 2015 - 8:42am | Financings
- November 12, 2015 - 10:10am | Research Notes
- November 3, 2015 - 8:30am | Research Notes
- October 5, 2015 - 8:06am | Research Notes, Regulatory
- July 29, 2015 - 10:52am | Earnings Alert
- July 26, 2015 - 11:46am | Research Notes
- July 18, 2015 - 3:33pm | Research Notes
- July 12, 2015 - 5:53pm | Research Notes
- July 5, 2015 - 3:07pm | Research Notes
- July 1, 2015 - 10:11am | Research Notes, Regulatory
- July 1, 2015 - 9:42am | Research Notes
- May 6, 2015 - 9:53am | News
- April 30, 2015 - 1:55pm | Regulatory
- February 25, 2015 - 7:15pm | Financings
- February 24, 2015 - 8:32am | Regulatory
- February 17, 2015 - 10:16am | Regulatory
- February 3, 2015 - 5:28am | BOD & C-Suite Updates
- January 30, 2015 - 7:09pm | Financings